| Project/Area Number |
26461385
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Endocrinology
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
Inaba Hidefumi 和歌山県立医科大学, 医学部, 講師 (70447770)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
赤水 尚史 和歌山県立医科大学, 医学部, 教授 (20231813)
西 理宏 和歌山県立医科大学, 医学部, 准教授 (90228148)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | バセドウ病 / TSH受容体 / HLA / T細胞 / HLA-DR / TSHR / Siglec |
|---|
| Outline of Final Research Achievements |
The aim of this study is 1) to elucidate epitope presentation in Graves’ disease (GD), and 2) to establish epitope specific therapy for GD. We have reported that human TSH receptor (AA78-94) was an important epitope. Therapeutic role of the mutant human TSH receptor peptide: 37m, was evaluated in this study. GD model of HLA-DR3 transgenic mice was treated with 37m. The thyrotoxicosis was improved, TRAb production was suppressed, and proportion of regulatory T-cells in the spleen was increased. Therefore, immune-regulatory effects of 37m were observed.
|
